After several decades, therapeutic cancer vaccines now show signs of efficacy and potential
to help patients resistant to other standard-of-care immunotherapies, but they have yet to …

Gliomas are the common type of brain tumors originating from glial cells. Epidemiologically,
gliomas occur among all ages, more often seen in adults, which males are more susceptible …

The remarkable clinical activity of chimeric antigen receptor (CAR) therapies in B cell and
plasma cell malignancies has validated the use of this therapeutic class for liquid cancers …

Chimeric antigen receptor (CAR) T cells have demonstrated promising efficacy, particularly
in hematologic malignancies. One challenge regarding CAR T cells in solid tumors is the …

Glioblastoma is the most common malignant primary brain tumor. Overall, the prognosis for
patients with this disease is poor, with a median survival of< 2 years. There is a slight …

This Review discusses the major advances and changes made over the past 3 years to our
understanding of chimeric antigen receptor (CAR) T cell efficacy and safety. Recently, the …

Improving the survival of patients with osteosarcoma has long proved challenging, although
the treatment of this disease is on the precipice of advancement. The increasing feasibility of …

Immunotherapy has become a powerful clinical strategy for treating cancer. The number of
immunotherapy drug approvals has been increasing, with numerous treatments in clinical …

Adoptive T cell transfer (ACT) is a new area of transfusion medicine involving the infusion of
lymphocytes to mediate antitumor, antiviral, or anti-inflammatory effects. The field has rapidly …

Most (if not all) tumors emerge and progress under a strong evolutionary pressure imposed
by trophic, metabolic, immunological, and therapeutic factors. The relative impact of these …